Irritable bowel syndrome affects about 10-15% of adults worldwide, causing abdominal pain, bloating, diarrhea, and constipation without visible damage to the gut. Current treatments include dietary changes, fiber supplements, antispasmodics, and newer gut-specific drugs like eluxadoline and rifaximin. Many people still struggle to find relief.
What's actually going on in research
Trials are testing gut-brain axis medications that target nerve signaling, bile acid modulators for diarrhea-predominant IBS, microbiome-based treatments including specific bacterial strains, and drugs that address visceral pain sensitivity. Researchers are also studying whether food sensitivities, SIBO, and mast cell activation drive symptoms in subgroups of patients.
Gut-brain medications
New drugs target nerve pathways between gut and brain, aiming to reduce pain signaling without causing constipation. Several are in late-stage trials after showing promise in pain reduction.
Microbiome treatments
Studies are testing specific bacterial strains and fecal microbiota transplant to see if restoring gut bacteria balance can reduce symptoms. Some trials focus on post-infection IBS where the microbiome appears disrupted.
Bile acid modulators
Drugs that bind excess bile acids show promise for diarrhea-predominant IBS. Trials are testing whether these work better than current antidiarrheals and whether bile acid malabsorption is more common than previously thought.
What to know before you search
Eligibility typically depends on IBS subtype (diarrhea, constipation, or mixed), symptom severity, whether you've tried standard treatments, and ruling out other conditions like IBD or celiac disease.
What types of trials are currently open
- Treatment trials — Testing new medications for pain, diarrhea, or constipation, usually comparing them to placebo over 8-12 weeks while you track symptoms daily.
- Dietary trials — Testing specific diets like low-FODMAP variations, fiber types, or elimination protocols to identify which foods trigger symptoms in different IBS subtypes.
- Microbiome trials — Testing probiotics, prebiotics, or fecal transplant to see if changing gut bacteria composition reduces symptoms.
- Biomarker studies — Collecting stool, blood, or breath samples to identify markers that might predict which treatments work for which people, or to find subgroups with distinct causes.
- Behavioral trials — Testing gut-directed hypnotherapy, cognitive behavioral therapy, or other approaches that address the brain's role in IBS symptoms.
Recently added Irritable Bowel Syndrome trials
The LITTLE OWLS Study (in German: "Kleine Eulen OWL"): Exploring the Early-life Microbiome Development and Physical and Mental Health Outcomes During Childhood.
The LITTLE OWLS study is a prospective, longitudinal birth cohort study investigating early-life microbiome development and its association with physical and mental health outcomes during childhood. Recruitment began in 2024, enrolling families from late pregnancy through the child's first 6 years of life, with a target of at least 1000- 1200 children and their families. The study characterizes longitudinal microbiome trajectories-including resilience and dysbiosis-and their relationship to common chronic diseases. Data are collected via online surveys, symptom and medication diaries, annual clinical exams, and repeated biological sampling of the child, mother, father/partner, siblings, and household environment. Findings are intended to support future diagnostics, prevention, and therapy for common chronic physical and mental diseases.
Abdominal Symptoms and Rosacea: An Observational Study on the Association Between Irritable Bowel Syndrome (IBS) and the Gut-Skin Axis
To describe the prevalence of rosacea in a population of patients with IBS followed at a tertiary-level university medical center.
Find Irritable Bowel Syndrome trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.